Maraviroc for Preexposure Prophylaxis

Preexposure prophylaxis (PrEP) with coformulated tenofovir and emtricitabine has been established as useful in preventing HIV infection. However, studies of this intervention in women have yielded conflicting results.

Now, investigators in the U.S. and Puerto Rico have conducted a randomized phase II study to test the safety and tolerability among women of PrEP containing maraviroc (MVC), a CCR5 antagonist of viral entry that has been approved for HIV treatment. The study included 188 HIV-negative participants (median age, 35 years; 65% black) who reported condomless vaginal or anal intercourse with at least one man with known HIV infection or unknown serostatus within 90 days before study entry. The women were randomized evenly to one of fo…